The U.S. Trade Representative launched an investigation into Germany’s drug pricing policies, arguing the U.S. shoulders a disproportionate share of biopharma R&D burden. USTR ambassador Jamieson Greer said the probe was initiated under Section 301 of the Trade Act of 1974, with a Sept. 22 public hearing expected. The filing points to Germany’s draft legislation aimed at saving more than €16 billion in healthcare spending and managing insurer rates, alongside reported efforts to reduce pharmaceutical expenditures. Drugmakers have objected, including Eli Lilly CEO David Ricks, and Reuters previously reported Germany dropped one contentious element. If USTR concludes Germany’s actions unreasonably impact U.S. interests, potential remedies could include confidential supplemental discounts or mandatory variable rate rebates—an outcome that could reshape commercial planning for multinational pharma.